Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
16 avr. 2024 08h30 HE
|
Palisade Bio, Inc.
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...